NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
14 trialsNCT04886531 2026-03-12
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05467891 2026-02-27
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06179303 2026-02-27
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT05501704 2026-01-07
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04569747 2025-11-13
ADEPT
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04553770 2025-11-10
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT02476786 2025-07-28
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
Phase 2 Recruiting
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT05472792 2025-05-23
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT05190094 2025-05-07
ICRG0201
International Cancer Research Group, United Arab Emirates
Phase 2 Recruiting
NCT04985266 2024-12-05
TRAK-ER
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT04666961 2022-04-22
HORNEO01
Institut Cancerologie de l'Ouest
Phase 2 Recruiting